Patient-derived organoids in ovarian cancer: Current research and its clinical relevance

Regardless of recent advances in cancer treatment, ovarian cancer (OC) patients have had a five-year survival rate of 48% in the last few decades. Diagnosis at the advanced stage, disease recurrence, and lack of early biomarkers are the severe clinical challenges associated with disease survival rate. Identifying tumor origin and developing precision drugs will effectively advance OC patient's treatment. The lack of a proper platform to identify and develop new therapeutic strategies in OC treatment necessitates searching for a suitable model to address tumor recurrence and therapeutic resistance. The development of the OC patient-derived organoid model provided a unique platform to identify the exact origin of high-grade serous OC, drug screening, and the development of precision medicine. This review provides an overview of recent progress in developing patient -derived organoids and their clinical relevance. Here, we outline their uses for transcriptomics and genomics profiling, drug screening, translational study, and their future perspective and clinical outlook as a model to advance OC research that could offer a promising approach for developing precision medicine.

Automated summary

Despite recent advances in cancer treatment, ovarian cancer patients continue to face challenges such as late-stage diagnosis, disease recurrence, and the lack of early biomarkers, resulting in a relatively low survival rate. The development of the patient-derived organoid model provides a unique platform for identifying tumor origin, drug screening, and precision medicine development, offering a promising approach in advancing ovarian cancer research. This review summarizes the progress in patient-derived organoids and their clinical relevance, highlighting their uses in transcriptomics, genomics profiling, drug screening, translational study, and their potential impact on precision medicine development in ovarian cancer.